# US 2025/0145671 A1 · Chimeric papillomavirus l1 protein > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2025/0145671 A1 - Document ID: US20250145671A1 - Status: Published application - Kind: A1 - Application number: 18/904,315 - Filed: 2024-10-02 - Published: 2025-05-08 - Earliest claimed: 2019-07-19 - Assignees: SinoCellTech Ltd. - Applicants: Sinocelltech Ltd. - Inventors: Liangzhi Xie; Chunxia Luo; Wei Zhang; Xiaoyan Suo; Lin Pang; Ping Hu - Web page: https://patentgrep.com/patent/US20250145671A1 ## CPC - C07K 14/005: from viruses - C07K 14/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus - A61K 39/12: Viral antigens - A61P 31/20: for DNA viruses - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61K 2039/5258: {Virus-like particles} - C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2710/20023: Virus like particles [VLP] - C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines. ## Claims ### Claim 1 A chimeric human papillomavirus L1 protein comprising, from its N-terminus to C-terminus orientation, (a) an N-terminal fragment derived from an L1 protein of HPV Type 56, wherein said fragment is encoded by the gene in SEQ ID No: 135; and (b) a C-terminal fragment, which is selected from the sequences shown in SEQ ID No: 2 or SEQ ID No: 132, wherein said chimeric human papillomavirus L1 protein has the immunogenicity of the L1 protein of the HPV type 56. ### Claim 2 (depends on 1) The chimeric human papillomavirus L1 protein according to claim 1, wherein the sequence of the N-terminal fragment derived from HPV type 56 L1 protein is shown in SEQ ID No: 131. ### Claim 3 (depends on 1) The chimeric human papillomavirus L1 protein according to claim 1, wherein said C-terminus of said N-terminal fragment is connected to the N-terminus of said C-terminal fragment directly or via a linker. ### Claim 4 (depends on 1) The chimeric human papillomavirus L1 protein according to claim 1, wherein the sequence of the chimeric HPV L1 is shown in SEQ ID No: 133. ### Claim 5 (depends on 1) An immunogenic composition for the prevention of papillomavirus-associated diseases, comprising: (a) an adjuvant; and (b) the chimeric human papillomavirus L1 protein according to claim 1. ### Claim 6 (depends on 2) An immunogenic composition for the prevention of papillomavirus-associated diseases, comprising: (a) an adjuvant; and (b) the chimeric human papillomavirus L1 protein according to claim 2. ### Claim 7 (depends on 3) An immunogenic composition for the prevention of papillomavirus-associated diseases, comprising: (a) an adjuvant; and (b) the chimeric human papillomavirus L1 protein according to claim 3. ### Claim 8 (depends on 4) An immunogenic composition for the prevention of papillomavirus-associated diseases, comprising: (a) an adjuvant; and (b) the chimeric human papillomavirus L1 protein according to claim 4.